Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIT101 vs MabThera vs Rituxan in RA
NCT02819726Phase 1Completed
- Sponsor
- Archigen Biotech Limited
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Archigen Biotech Limited. Primary endpoints: Area Under the Concentration Time Curve From Time 0 to Last Quantifiable Concentration at Week 24, Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity at Week 24 and 4 more. Started Oct 2016; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02819726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819726.